Table III.
A, Proportion of patients | |||
---|---|---|---|
Prognostic factors | Kagoshima | Katagiri (2005) | P-value |
Primary lesiona | 0.65b | ||
Rapid growth | 52 | 132 | |
Moderate growth | 42 | 74 | |
Slow growth | 51 | 144 | |
Visceral and cerebral metastasis | <0.01c | ||
Yes | 37 | 178 | |
No | 108 | 172 | |
Performance status (ECOG) | <0.01c | ||
3 or 4 | 61 | 219 | |
1 or 2 | 84 | 131 | |
Previous chemotherapy | 0.47c | ||
Yes | 46 | 108 | |
No | 99 | 241 | |
Skeletal metastases | <0.01c | ||
Multiple | 80 | 238 | |
Single | 65 | 112 | |
B, Katagiri scoring | |||
Scoring | All patients Kagoshima | All patients Katagiri (2005) | P-value |
0–2 | 31 | 23 | <0.01b |
3–5 | 54 | 67 | |
6–8 | 60 | 156 | |
C, Katagiri scoring | |||
Prognostic score | Months | Survival rate (%) | 95% CI |
0–2 points | 3 | 78.0 | 0.66–0.90 |
6 | 69.7 | 0.56–0.84 | |
12 | 66.5 | 0.52–0.81 | |
24 | 38.2 | 0.20–0.57 | |
3–5 points | 3 | 63.5 | 0.52–0.75 |
6 | 52.0 | 0.40–0.64 | |
12 | 29.0 | 0.17–0.41 | |
24 | 21.8 | 0.11–0.33 | |
6–8 points | 3 | 64.5 | 0.45–0.84 |
6 | 29.8 | 0.10–0.49 | |
12 | 13.2 | 0.00–0.29 | |
24 | 6.61 | 0.00–0.19 |
Primary lesions in hepatocellular, gastric, lung carcinoma, other carcinoma and sarcoma, breast, prostate, thyroid carcinoma
measured with Mann-Whitney test
measured with Fisher's exact probability test. ECOG, Eastern Cooperative Oncology Group; CI, confidence interval.